Centre Hospitalier Universitaire Amiens Picardie

At Centre Hospitalier Universitaire Amiens Picardie, the Pneumology team is leading studies in respiratory tract diseases and related lung conditions, with a strong focus on improving care for patients with chronic and infectious pulmonary disorders. Research includes testing new treatment options, assessing long-term safety, and evaluating ways to better control symptoms and disease progression.

• Bronchiectasis and early airway infection: studies aimed at improving infection control and treatment effectiveness
• Fibrotic lung disease: research on long-term safety and symptom management in progressive lung conditions
• Mycobacterium xenopi pulmonary infection: trials testing new approaches for difficult-to-treat respiratory infections
• Ventilator-associated pneumonia: evaluation of antibiotic strategies for critically ill patients

This area reflects a broader effort to strengthen pulmonary infection care, chronic lung disease management, and practical treatment choices for patients in hospital and intensive care settings.

The site has an active portfolio in neoplasms and hemic and lymphatic diseases, covering both solid tumors and blood cancers. These trials are designed to evaluate new therapies, compare treatment combinations, and improve outcomes for patients with advanced or relapsed disease.

• Acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis: studies focused on transplant outcomes, disease control, and new targeted treatments
• Diffuse Large B-Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia: research evaluating novel immunotherapy and combination strategies
• Breast cancer, prostate cancer, and small bowel adenocarcinoma: trials comparing treatment effectiveness and refining disease-free or progression-free survival
• Melanoma and hepatocellular carcinoma: investigations of new immune-based and targeted approaches for advanced cancer

This oncology program emphasizes both treatment effectiveness and clinical benefit, with several studies exploring how to extend survival while maintaining tolerability.

Clinical research in immune system diseases and related inflammatory conditions is an important part of the portfolio, alongside studies supporting transplant care. The trials aim to reduce disease activity, prevent rejection, and improve long-term safety in patients with complex immune-mediated disorders.

• Sjögren's syndrome and lupus nephritis: studies assessing new therapies for autoimmune inflammation
• Crohn's disease: research focused on maintaining response and improving symptom control in inflammatory bowel disease
• Kidney transplant: trials designed to prevent rejection and support graft survival
• Prurigo nodularis: evaluation of treatments intended to relieve chronic inflammatory skin symptoms

These studies reflect a strong interest in immune regulation, transplant rejection prevention, and better management of chronic inflammatory disease.

The site also contributes to nervous system diseases research, especially in migraine and neuropathic pain. Trials in this area are exploring preventive options, symptom relief, and safer long-term use of treatments for children, adolescents, and adults.

• Migraine, episodic migraine, and chronic migraine: studies testing preventive therapies and symptom reduction
• Chronic post-surgical or post-traumatic neuropathic pain: research aimed at improving pain relief in adolescents
• Cardiac and neurological overlap conditions: selected studies examining outcomes relevant to broader neurologic and systemic care
• Pediatric headache disorders: investigations focused on long-term safety and tolerability of treatment options

Overall, this field centers on better symptom control and treatment safety for common but often disabling neurologic conditions.

Another important research direction at Centre Hospitalier Universitaire Amiens Picardie involves bacterial infections and mycoses, cardiovascular diseases, and acute care conditions. These trials are designed to improve infection treatment, support critically ill patients, and evaluate therapies that may reduce clot-related complications.

• Candidemia and invasive candidiasis: studies testing new antifungal treatment strategies
• Proximal deep vein thrombosis: research assessing clot breakdown and treatment safety
• Intensive care and post-cardiac arrest shock: trials focused on supportive care and recovery outcomes
• Arrhythmogenic right ventricular dysplasia and cardiac arrest: investigations into cardiac protection and disease monitoring

This portfolio highlights efforts to improve acute care outcomes, reduce infection-related harm, and refine treatment decisions in high-risk medical settings.